HC Wainwright & Co. reiterated coverage of NeuBase Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously

HC Wainwright & Co. reiterated coverage of NeuBase Therapeutics with a rating of Buy and set a new price target of $18.00 from $15.00 previously

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today reported that it received a notice (the "Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule") as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Form 10-K") in a timely manner. This Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market. Under Nasdaq rule

ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation ("Symetryx") and their subsequent press release issued on September 6, 2023. "The NeuBase Board of Directors ("Board") appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value. The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetr

URGES BOARD TO CONSIDER A $1 DIVIDEND TORONTO, Sept. 6, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ:NBSE) ("Neubase"). Symetryx is now urging the Board to issue a special $1 per share dividend. Symetryx has bought these shares on the open market and intends to engage with the management of Neubase to chart the best path forward for shareholders. Neubase, as disclosed in its previous news releases, is currently undergoing a strategic review of the company's operations. Symetryx notes that for the quarter ended June 30, 2023, Neubase reported approximate cash bala

PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that its Board of Directors (the "Board") has completed a review of the Company's business, including the status of its programs, resources, and capabilities. The Board has made the determination to halt further development of the Company's programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, the Board will explore potential strategic a

PITTSBURGH, June 30, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 578,697 of its shares of common stock (or common stock equivalents) at a purchase price of $2.57 per share (or common stock equivalent) and associated unregistered warrants and concurrent private placement of an aggregate of 1,366,829 of its shares of common stock (or common stock equivalents), at the same purchase price of $2.57

PITTSBURGH, June 28, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 578,697 of its shares of common stock (or common stock equivalents) in a registered direct offering at a purchase price of $2.57 per share (or common stock equivalent) and associated unregistered warrants. In a concurrent private placement, NeuBase has also agreed to issue and sell an aggregate of 1,366,829 of its shares of common stock (or common s

PITTSBURGH, June 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, to be effective as of 5:00 p.m. Eastern Time today, June 14, 2023. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Thursday, June 15, 2023. Following the reverse stock split, the Company's common stock will continue to trade on The Nasdaq Capital Market under the

PITTSBURGH, May 24, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that the Company's management will participate in the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on June 7-9, 2023. Presentation Details for the Jefferies Healthcare Conference CompanyNeuBase TherapeuticsDate:Friday, June 9, 2023Time:8:00 a.m. ETRoom:Track 1Format:Corporate Presentation A live webcast of the Company's presentation will be available at https://wsw.com/webcast/jeff281/nbse/1841840 and

Data show that Stealth Editors™ achieve ex vivo gene editing using simple synthetic reagents to harness the cell's own high-fidelity editing machineryData show that Stealth Editors™ do not elicit a cell-based immunity and promise a non-immunogenic in vivo solution Data show that Stealth Editors™ can be encapsulated via established lipid nanoparticle technologies promising a non-immunogenic delivery solution and a de-risked pathway to address therapeutic targets in the liverData featured in an oral presentation at the American Society of Gene & Cell Therapy ("ASGCT") 2023 Annual Meeting Company to present additional data showcasing gene editing capabilities of Stealth Editors™ throughout rema

PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation ("Symetryx") and their subsequent press release issued on September 6, 2023. "The NeuBase Board of Directors ("Board") appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value. The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetr

URGES BOARD TO CONSIDER A $1 DIVIDEND TORONTO, Sept. 6, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ:NBSE) ("Neubase"). Symetryx is now urging the Board to issue a special $1 per share dividend. Symetryx has bought these shares on the open market and intends to engage with the management of Neubase to chart the best path forward for shareholders. Neubase, as disclosed in its previous news releases, is currently undergoing a strategic review of the company's operations. Symetryx notes that for the quarter ended June 30, 2023, Neubase reported approximate cash bala

Data show that Stealth Editors™ achieve ex vivo gene editing using simple synthetic reagents to harness the cell's own high-fidelity editing machineryData show that Stealth Editors™ do not elicit a cell-based immunity and promise a non-immunogenic in vivo solution Data show that Stealth Editors™ can be encapsulated via established lipid nanoparticle technologies promising a non-immunogenic delivery solution and a de-risked pathway to address therapeutic targets in the liverData featured in an oral presentation at the American Society of Gene & Cell Therapy ("ASGCT") 2023 Annual Meeting Company to present additional data showcasing gene editing capabilities of Stealth Editors™ throughout rema

Announced oral presentations at the American Society of Gene & Cell Therapy ("ASGCT") 26th Annual Meeting to take place on May 16-20, 2023 Company to present additional data showcasing gene editing capabilities at scientific conferences throughout remainder of 2023 PITTSBURGH, May 11, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments. "To date in 2023, we have made steady progress advancing the development o

A single intravenous dose of NeuBase's Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescues splicing, restores chloride channel (Clcn1) function, and durably reverses myotonia in the HSALR modelMultiple subcutaneous doses also lead to molecular and functional rescue in the HSALR model demonstrating efficacy in a dose-dependent manner and potential feasibility of this patient-friendly administration routeCompany remains on track to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in 4Q CY2022NeuBase management to host a conference call and webcast tomorrow, March 14, at 8:00 a.m. EDT PITTSBURGH and CAMBRIDGE,

Extended cash runway into CY2023 following completion of an equity financing from leading healthcare investors generating $42.6 million in net proceeds; supports advancing the Company's lead program into the clinic and scaling of its precision genetic medicine pipelineCompleted acquisition of peptide-nucleic acid ("PNA") scaffold technologies, to expand the PATrOL™ platform capabilities and consolidate PNA intellectual propertyScheduled to host an R&D day on June 8th to present new preclinical data, updates on myotonic dystrophy type 1 (DM1) and Huntington's disease (HD) programs, and unveil a new program in oncology PITTSBURGH, May 13, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc.

Recently demonstrated single-dose intravenous administration of a PATrOL™-enabled compound resolves the causal genetic defect in myotonic dystrophy type 1 (DM1) in transgenic animals; Company on course to move one program into clinical development in CY2022 Plans to host an R&D day in the first half of CY2021 to provide updates on platform innovations, the DM1 and Huntington's disease (HD) programs and pipeline expansion in high value indications Expects to complete consolidation of intellectual property in the space through acquisition of gene modulating technology from Vera Therapeutics in Q1 CY2021 PITTSBURGH, Feb. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBS

5 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

4 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

3/A - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

4 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

4 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

3 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

4 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

4 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

4 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)

4 - NeuBase Therapeutics, Inc. (0001173281) (Issuer)